可比司他与利托那韦增强达芦那韦的脑脊液浓度比较
该开放单臂序贯临床试验纳入7例HIV相关神经认知障碍患者,比较达芦那韦/利托那韦(800/100 mg每日一次)与达芦那韦/可比司他(800/150 mg每日一次)方案下脑脊液达芦那韦浓度。结果显示两种增强剂下脑脊液浓度无显著差异,均超过IC50和IC90,患者脑脊液和血浆病毒载量持续抑制。
要点
- 可比司他与利托那韦增强的达芦那韦脑脊液浓度无显著差异(P=0.58)。
- 两种方案下达芦那韦脑脊液浓度均超过IC50和IC90,病毒学持续抑制。
- 两种增强剂在每日一次达芦那韦方案中可互换使用。
核心结论
- 可比司他和利托那韦增强的达芦那韦在脑脊液中产生相当的有效浓度,提示两种增强剂在每日一次达芦那韦方案中可互换使用。
研究设计与样本
- 开放、单臂、序贯临床试验(NCT02503462),纳入7例HIV相关神经认知障碍患者。
- 患者先接受达芦那韦/利托那韦(800/100 mg)每日一次,后换用达芦那韦/可比司他(800/150 mg)每日一次,采集配对脑脊液和血样。
主要发现
- 利托那韦和可比司他增强的脑脊液达芦那韦浓度中位数(IQR)分别为16.4 ng/mL(8.6-20.3)和15.9 ng/mL(6.7-31.6),P=0.58。
- 脑脊液:血浆达芦那韦比值中位数(IQR)分别为0.007(0.006-0.012)和0.011(0.007-0.015),P=0.16。
- 利托那韦增强时脑脊液达芦那韦浓度超过IC50和IC90的中位数倍数分别为9.2倍和6.7倍,可比司他增强时分别为8.9倍和6.5倍。
- 所有患者脑脊液达芦那韦浓度均高于目标抑制浓度,脑脊液和血浆病毒载量持续抑制。
临床怎么用
- 对于需要每日一次达芦那韦方案的HIV相关神经认知障碍患者,可比司他可替代利托那韦作为增强剂。
局限性
- 样本量小(仅7例患者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cobicistat and ritonavir have different inhibitory profiles for drug transporters that could impact the distribution of co-administered drugs. We compared darunavir concentrations in CSF when boosted by cobicistat versus ritonavir relative to plasma concentrations and with WT HIV-1 IC50 and IC90. METHODS: An open, single-arm, sequential clinical trial (NCT02503462) where paired CSF and blood samples were taken from seven HIV-infected patients presenting with HIV-associated neurocognitive disorders (HAND) and treated with a darunavir/ritonavir (800/100 mg) once-daily regimen. Ritonavir was subsequently replaced by cobicistat and paired CSF and blood samples were obtained from the same patients after treatment with the darunavir/cobicistat (800/150 mg) once-daily regimen. Darunavir concentrations at the end of the dosing interval were quantified by LC-MS/MS. RESULTS: The median (IQR) darunavir concentrations in CSF with ritonavir and cobicistat boosting were 16.4 ng/mL (8.6-20.3) and 15.9 ng/mL (6.7-31.6), respectively (P = 0.58). The median (IQR) darunavir CSF:plasma ratios with ritonavir and cobicistat boosting were 0.007 (0.006-0.012) and 0.011 (0.007-0.015), respectively (P = 0.16). Darunavir concentrations in CSF exceeded the darunavir IC50 and IC90 by a median of 9.2- and 6.7-fold with ritonavir boosting, and by 8.9- and 6.5-fold with cobicistat boosting, respectively. All patients had darunavir CSF concentrations above the target inhibitory concentrations and remained virologically suppressed in the CSF and plasma. CONCLUSIONS: This small study shows that cobicistat and ritonavir give comparable effective darunavir concentrations in CSF, thus suggesting that these boosters can be used interchangeably in once-daily darunavir regimens.
引用
- Bartels H, Decosterd L, Battegay M, et al. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. J Antimicrob Chemother. 2017. PMID: 28575323. doi:10.1093/jac/dkx165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。